How to Cite
Abstract
The aim of the study was to conduct clinical and economic analysis of the feasibility of using Dicarbamine® for the prevention of toxic effects of chemotherapy. There were compared the direct medical costs on prevention and treatment of febrile neutropenia in 2 groups of breast cancer patients: chemotherapy alone in TAC mode or chemotherapy in the same way against oral Dicarbamine ®. Total costs due to hematologic toxicity were 1003945 rubles in the control group (22817 rubles on average by 1 patient) and 658980 rubles in the group treated with Dicarbamine ® (14 644 rubles on average by 1 patient). Also, the study found that in the group treated by Dicarbamine there were lower rates of dose reduction and delay of the next course of chemotherapy, which might have an impact on other costs arising from cancer. The results of this study demonstrate the clinical and economic feasibility of using Dicarbamine ® for the prevention of hematotoxic complications of chemotherapy.References
Бычков М.Б., Бесова Н.С., Топчиева С.В. и др. Окончательные результаты кооперированных исследований препаратв дикарбамин в качестве гемапротектора при комбинированной химиотерапии у онкологических больных // Вопр. онкол. — 2009. — Т. 55. -С. 627-633.
Гарин А.М., Горбунова В.А., Бычков М.Б. и др. Результаты кооперированного клинического изучения препаратв дикарбамин по II фазе в качестве протектора лейкопоэза у онкологических больных в условиях миелосупрессивной химиотерапии // Вопр. онкол. — 2004. — Т. 50. — С. 184-188.
Гершанович М.Л., Филатова Л.В. Эффективность дикарбамина в качестве протектора миелодепрессии у больных Лимфомой Ходжкина при комбинированной химиотерапии // Вопр. онкол. — 2007. — Т. 53. — С. 589-595.
Орлова Р. В., Чубенко В. А. Фебрильная нейтропения. Инфекционно-токсический шок // Практ. онкол. - 2006. — № 2 - С. 69-76.
Aapro M.S., Bohlius J., Cameron D.A., et al. Update of EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours // Eur J Cancerio - 2011. — Vol. 47. - P. 8-32.
Bonadonna G., Valagussa P., Moliterni A. et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer // N Engl J Med 1995. - Vol. 332. - P. 901-906.
Bonneterre J., Roch H., Kerbrat P. et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial // J Clin Oncol. - 2005. - Vol. 23. - P. 2686-2693.
Budman Dr., Berry Da., Cirrincione C.T., et al., Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer // J Natl Cancer Inst. - 1998. - Vol. 90. - P. 1205-1211.
Chirivella I., Bermejo A., Insa A. et al. Impact of chemotherapy dose-related factors on survival in breast cancer patients treated with adjuvant anthracycline-based chemotherapy // J Clin Oncol. - 2006. - Vol. 24. - abstr. 668.
Leonard R.C.F., Miles D., Thomas R., Nussey F. UK Breast Cancer Neutropenia Audit Group Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients // Br J Cancer. — Vol. 89. - P. 2062-2068.
Lyman G.H., Kuderer N.M., Agboola O. et al. The epidemiology and economics of neutropenia in hospitalized cancer patients: data from the university health // System Consortium. Blood. - 2001. - Vol. 98. - P. 432a. - abstr.
Lyman G.H., Kuderer N., Greene J., Balducci l. The economics of febrile neutropenia: implications for the use of colony-stimulating factors // Eur J Cancer. - 1998. - Vol. 34. - P. 1857-1864.
Morrison V.A., Picozzi V., Scott S., et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis // Clin Lymphoma. — 2001. - Vol. 2. - P. 47-56.
National Comprehensive Cancer Network. Myeloid growth factors v1020012 (http://www.nccn.org).
Smith T.J., Khatcheressian J., Lyman G.H. et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline // J Clin Oncol. - 2006. - Vol. 24. - P. 3187-3205.
Trillet-Lenoir V., Green J., Manegold C. et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy // Europ J. Cancer. — 1993. — Vol. 29A. — P. 319-322.
Wood W.C., Budman D.R., Korzun A.H. et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma // N Engl J Med. - 1994. - Vol. 330. - P. 1253-1259.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...